CN108497478A - A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application - Google Patents
A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application Download PDFInfo
- Publication number
- CN108497478A CN108497478A CN201810157269.9A CN201810157269A CN108497478A CN 108497478 A CN108497478 A CN 108497478A CN 201810157269 A CN201810157269 A CN 201810157269A CN 108497478 A CN108497478 A CN 108497478A
- Authority
- CN
- China
- Prior art keywords
- parts
- water
- food
- health products
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 230000036039 immunity Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000009636 Huang Qi Substances 0.000 claims abstract description 11
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 10
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 10
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 235000019441 ethanol Nutrition 0.000 claims description 33
- 239000000463 material Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 7
- 229940013618 stevioside Drugs 0.000 claims description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000001116 FEMA 4028 Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
- 229960004853 betadex Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004302 potassium sorbate Substances 0.000 claims description 2
- 235000010241 potassium sorbate Nutrition 0.000 claims description 2
- 229940069338 potassium sorbate Drugs 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 208000033065 inborn errors of immunity Diseases 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229920002527 Glycogen Polymers 0.000 description 7
- 241000229143 Hippophae Species 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000001541 thymus gland Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 6
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 206010014025 Ear swelling Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 101150110933 PHY gene Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- CJDPJFRMHVXWPT-UHFFFAOYSA-N barium sulfide Chemical compound [S-2].[Ba+2] CJDPJFRMHVXWPT-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of food, health products or pharmaceutical compositions, it is the preparation that the raw material matched by following weight is prepared：200~300 parts of Radix Astragali, 200~300 parts of matrimony vine, 250~400 parts of Herba Epimedii, 150~300 parts of sea-buckthorn.The present invention also provides the preparation method of above-mentioned composition and purposes.The experimental results showed that composition of the invention can effectively eliminate fatigue and the immunity of enhancing body.And the present composition is medicinal and edible Chinese medicine, safe and non-toxic, is suitble to be used for a long time, and is suitable for hypoimmunity and excessively tired sub-health population, a kind of new selection is provided for clinical application.
Description
Technical field
The present invention relates to a kind of food of strengthen immunity, health products or pharmaceutical compositions and its preparation method and application.
Background technology
The World Health Organization (WHO) by body without organic disease, but have some functions change state be known as " third
State " is known as " sub-health state " in China, refers specifically to no clinical symptoms and sign, or have illness to feel and examined without clinic
Evidence, but the information of existing potential morbidity tendency are investigated, the low-quality and the heart that a kind of housing construction is degenerated and physiological function declines are in
Manage imbalance state.With the quickening of social life rhythm, people's diet is irregular, rhythm of life is disorderly, has not enough sleep, is excessively tired
Labor does not get enough athletic exercise, the influences such as bad life styles and environmental pollution such as excessive drinking of smoking, and psychology, body are chronically at fatigue state,
The disorder for causing stomach function equilibrium system directly or indirectly damages gastric mucosa, and immunity reduces, and disease resistance declines, to
Cause " sub-health state " of whole body.Show as weak all over, dizzy eye is puckery, palpitation, insomnia forgetfulness, excessive internal heat constipation；Exempt from
Epidemic disease power reduces, and easily catches a cold and epidemic disease；If encountering height stimulates, it is easy to occur dying suddenly.Current sub-health population exists
Countries in the world generally existing, number rise year by year, and are in rejuvenation trend.The global sex inventory of one of WHO is bright, 75% people
In " sub-health state ".In the related system that " the 21 century China's inferior health market academy's successes seminar " that Beijing is held provides
Meter data is shown, in China, existing 900,000,000 populations are in " sub-health state " at present, account for the 70% of total population, 15% people is in
Morbid state, only 15% people are in health status.The scale and severity of sub-health population have allowed of no optimist and " have sat
Depending on ".
Prevention " inferior health " key is to improve immunity and relieve fatigue.Either " Asia is strong caused by which kind of reason
Health ", it is main, most it is essential that human autoimmune's function reduction and excessively tired regardless of " inferior health " of performance.
Currently, work rhythm is accelerated, life stress enhancing, and most random eating habits of people lack physical training, various
Bad life style and behavior, the influence of extraneous adverse circumstances, causes body immunity to decline in addition.And with quality of life
It improves, people are changed from treating the health care into prevention, thing in advance afterwards.Urban and rural residents are all to health care attention degree and day
Increase.
Currently, the product market of China's strengthen immunity accounts for about the 60% of whole market share based on drug, hormone；
Supplemented by health food, account for about 35%, other account for 15%.Although drug effect is more apparent, drug resistance caused by long-term administration resists
Pharmacological property, lesions of liver and kidney etc. may generate damage to consumer；Although health food has no toxic and side effect to human body, can be according to oneself
Actual needs take, but the health-care effect of health products in recent years in the market is irregular.
Therefore, research and development are with immunological enhancement, antifatigue effect and safely and effectively the product of medicine-food two-purpose is compeled in eyebrow
Eyelash.
Invention content
In order to solve the above technical problem, the present invention provides a kind of food, health products or pharmaceutical compositions, it is under
State the preparation that the raw material of weight proportion is prepared：
200~300 parts of Radix Astragali, 200~300 parts of matrimony vine, 250~400 parts of Herba Epimedii, 150~300 parts of sea-buckthorn.
Further, the weight proportion of the raw material is：
250 parts of Radix Astragali, 250 parts of matrimony vine, 300 parts of Herba Epimedii, 200 parts of sea-buckthorn.
Further, the food, health products or pharmaceutical composition are by the medicinal powder of bulk pharmaceutical chemicals, the water of bulk pharmaceutical chemicals or organic
Solvent extractable matter is active constituent, in addition the preparation that acceptable auxiliary material is prepared in pharmacy.
Wherein, the auxiliary material be selected from sodium benzoate, potassium sorbate, ethyl-para-hydroxybenzoate, propylparaben,
One kind or more in butyl p-hydroxybenzoate, stevioside, xylitol, Aspartame, dextrin, soluble starch, beta-cyclodextrin
Kind.
Further, the preparation is oral preparation.
Further, the oral preparation is granule, pill, tablet, capsule, oral solution.
The present invention also provides a kind of methods preparing above-mentioned food, health products or pharmaceutical composition, it includes following step
Suddenly：
(1) each raw material is weighed by weight ratio；
(2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, and in pharmacy acceptable auxiliary material or it is complementary at
Divide and is prepared into preparation.
Further, it includes the following steps：
(1) each raw material is weighed by weight ratio, 8~12 times of water are added, is impregnated 30~60 minutes, is decocted 1~2 hour, mistake
Filter takes filter residue, and 8~12 times of water are added, and decocts 1~2 hour, filtering, merges filtrate twice, concentration；
(2) concentrate in step (1) is taken, adds ethyl alcohol that alcohol content is made to be 30~70%, stirs evenly, remove ethyl alcohol, concentrate,
The water of 1 times of amount of concentrate is added, stirs evenly, adds auxiliary material.
Further, it includes the following steps：
(1) each raw material is weighed by weight ratio, 8 times of water are added, is impregnated 60 minutes, is decocted 2 hours, and filtering takes filter residue, adds
Enter 8 times of water, decoct 2 hours, filtering merges filtrate twice, concentration；
(2) concentrate in step (1) is taken, adds ethyl alcohol that alcohol content is made to be 60%, stirs evenly, remove ethyl alcohol, concentrate, be added
The water of 1 times of amount of concentrate, stirs evenly, adds stevioside, xylitol, sodium benzoate.
The present invention also provides above-mentioned compositions to prepare food, health products or the drug for improving immunity and relieving fatigue
In purposes.
The experimental results showed that composition of the invention can effectively eliminate fatigue and the immunity of enhancing body.And
The present composition is medicinal and edible Chinese medicine, safe and non-toxic, is suitble to be used for a long time, and is suitable for hypoimmunity and excessively fatigue
Sub-health population, provide a kind of new selection for clinical application.
Monarch drug in a prescription Herba Epimedii returns liver and kidney channel in prescription of the present invention, has effects that kidney-replenishing, strengthening the bones and muscles；Ministerial drug Radix Astragali returns spleen,
Lung channel has the effect of invigorating qi for strengthening superficies, help spleen and lung, strengthening exterior and reducing sweat；Adjutant matrimony vine Return liver kidney channel has benefiting shrewd head, nourishing
The effect of liver kidney；Make medicine sea-buckthorn returns spleen, stomach, lung, the heart channel of Hang-Shaoyin, have nourishing Yin and promoting production of body fluid, cough-relieving apophlegmatic, relieving dyspepsia, promoting blood circulation to remove blood stasis
Effect.Four medicines share, and the effect of having gas essence filling, raise internal organs, compatibility is precise and appropriate can to play the imperial evil ability of antifatigue and enhancing
The effect of equal health cares.
Obviously, the above according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific implementation mode of form by the following examples remakes further specifically the above of the present invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on the above of the present invention
The technology realized all belongs to the scope of the present invention.
Specific implementation mode
The preparation of embodiment 1, food of the present invention, health products or pharmaceutical composition
1 prescription：Radix Astragali 250g, matrimony vine 250g, Herba Epimedii 300g, sea-buckthorn 200g.
2 auxiliary materials：Dextrin, soluble starch
3 preparation methods：Weigh above-mentioned four tastes raw material by weight ratio, add 8 times of water amount, impregnate 1 hour, decoct altogether it is secondary,
2 hours every time, collecting decoction, filtration was concentrated into thick paste [relative density is 1.30~1.35 (50 DEG C~60 DEG C)].By dextrin,
Soluble starch (thick paste in proportion：Dextrin：Soluble starch=1:2:1) it is added in thick paste and prepares softwood, then with fashion of extrusion
Sieved and pelletized by 18 mesh, dry at 70 DEG C, whole grain, packaging to get.
Application method：It takes twice daily, each 20g.
The preparation of embodiment 2, food of the present invention, health products or pharmaceutical composition
1 prescription：Radix Astragali 200g, matrimony vine 200g, Herba Epimedii 250g, sea-buckthorn 150g.
2 auxiliary materials：Butyl p-hydroxybenzoate (0.2g/kg), stevioside (0.16g/kg), xylitol (150g/kg).
3 preparation methods：Weigh above-mentioned four tastes raw material by weight ratio, add 8 times of water amount, impregnate 1 hour, decoct altogether it is secondary,
2 hours every time, collecting decoction filtered, concentration, room temperature to be cooled to, and adds ethyl alcohol that alcohol content is made to be 60%, stirs evenly, after standing, take
Clear liquid recycles ethyl alcohol, and it is 1.10-1.15 (90~95 DEG C) to be concentrated into relative density, and in concentrate plus distilled water is to nearly total amount,
It stirs evenly, stands, filter, stevioside, xylitol, butyl p-hydroxybenzoate, adjust pH value to 7, add water to 2000ml, stir
It is even, stand, filtration, it is filling, sterilizing to get.
Specification：Every bottle of 30ml takes orally, 2 times a day, a 30ml.
The preparation of embodiment 3, food of the present invention, health products or pharmaceutical composition
1 prescription：Radix Astragali 250g；Matrimony vine 250g；Herba Epimedii 300g；Sea-buckthorn 200g.
2 auxiliary materials：Sodium benzoate (0.2g/kg), stevioside (0.16g/kg), xylitol (150g/kg)
3 preparation methods：Weigh above-mentioned four tastes raw material by weight ratio, add 8 times of water amount, impregnate 1 hour, decoct altogether it is secondary,
2 hours every time, collecting decoction filtered, concentration, room temperature to be cooled to, and adds ethyl alcohol that alcohol content is made to be 60%, stirs evenly, after standing, take
Clear liquid recycles ethyl alcohol, and it is 1.10-1.15 (90~95 DEG C) to be concentrated into relative density, and in concentrate plus distilled water is to nearly total amount,
It stirs evenly, stands, filter, stevioside, xylitol, butyl p-hydroxybenzoate, adjust pH value to 7, add water to 2000ml, stir
It is even, stand, filtration, it is filling, sterilizing to get.
Specification：Every bottle of 30ml takes orally, 2 times a day, a 30ml.
Embodiment 4, food of the present invention, the preparation of health products or composite medicine
1 prescription：Radix Astragali 300g；Matrimony vine 300g；Herba Epimedii 400g；Sea-buckthorn 300g.
2 auxiliary materials：Dextrin, soluble starch
3 preparation methods：With embodiment 1
Application method：It takes twice daily, each 15g.
The screening of embodiment 5, present composition extraction process
1, extraction process by water screens
The total 70g of four traditional Chinese medicine is taken in 3 prescription ratio of embodiment, is tested by above-mentioned experiment condition, measures extract respectively
Content (%, w/w) and total saponin content (mg/ml) in terms of Astragaloside IV.It is measured as finger with extract content and total saponin content
Mark, preferably extraction conditions, experimental result are shown in Table 1.
1 abstract methods test result of table
1), extract content measures
3, confirmatory experiment
Precision measures each tested number sample solution 1ml, sets to have dried and dries to constant weight into the evaporating dish of constant weight in 105 DEG C,
It moves in drier, 30 minutes cooling, rapid accurately weighed weight calculates the content (%, w/w) of extract in test sample.It surveys
Fixed number evidence is shown in Table 1.
2) total saponin content measures
The preparation of a reference substance solutions：Astragaloside IV reference substance 2.64mg is taken, it is accurately weighed, it sets in 25ml measuring bottles, adds methanol
To scale, shake up to get (containing Astragaloside IV 0.1056mg in per 1ml).
The preparation of b test solutions：Precision draws each tested number sample solution 1ml, passes through D101 large pore resin absorption columns
(internal diameter 1.5cm, long 12cm) is eluted with water 50ml, is discarded aqueous, then eluted with 30% ethyl alcohol 50ml, is discarded 30% ethyl alcohol and wash
De- liquid elutes after with 90% ethyl alcohol 50ml, collects eluent, be evaporated, residue methanol is dissolved and is transferred in 10ml measuring bottles, is added
Methanol to scale, shake up to get.
The selection of c maximum absorption wavelengths：Above-mentioned reference substance solution 3ml, test solution 1ml are measured respectively, set 10ml tools
Solvent is volatilized in plug test tube, 5% vanillic aldehyde glacial acetic acid solution 0.2ml, perchloric acid 0.8ml is added, sets 15min in 70 DEG C of water-baths,
Cooling in ice-water bath is put in taking-up, and glacial acetic acid 5ml is added, shakes up, and with reagent, (reagent refers to its in addition to reference substance and test sample
Remaining reagent) it is blank, spectral scan is carried out within the scope of 400nm~700nm, measurement result shows test solution, Radix Astragali first
Glycosides reference substance solution has absorption maximum in 581nm, therefore determines that 581nm is to measure wavelength.
The preparation of d standard curves：Reference substance solution 0.5,1.0,1.5,2.0,2.5ml is taken to be volatilized in 10ml test tubes respectively
5% vanillic aldehyde glacial acetic acid solution 0.2ml, perchloric acid 0.8ml is added in solvent, precision, sets 15min in 70 DEG C of water-baths, and ice is put in taking-up
It is cooling in water-bath, glacial acetic acid 5ml is added, shakes up, using reagent as blank, trap is measured in 598nm, is vertical sit with trap
Mark, a concentration of abscissa of Astragaloside IV obtain regression equation A=21.105C+0.0437 (r=0.998), in 0.0067mg/ml-
Linear relationship is good within the scope of 0.033mg/ml.
E study on the stability
The aforementioned Astragaloside IV reference substance solution to have developed the color is taken, is placed at room temperature for, trap is measured at 581nm wavelength, with
First time minute is denoted as 0 minute, was measured every 10~20 minutes once, is measured 6 times altogether, the results are shown in Table 2.
2 stability experiment of table
The less stable the result shows that solution develops the color, therefore should be measured in 30 minutes after colour developing when experimental implementation.
F Precision Experiments
Same reference substance solution, replication trap 5 times is taken to the results are shown in Table 3.
3 Precision Experiment of table
The result shows that accuracy is good.
G determination of recovery rates
Precision draws known content (3.11mg/ml) sample liquid 0.3ml, and Astragaloside IV reference substance solution 1.5ml is added
(a concentration of 0.391mg/ml of reference substance) prepares test solution according to b methods under 2) item, is operated according to d methods under 2) item, in
Trap is measured at 581nm.Total saponin content in sample is calculated by calibration curve method and calculates its sample recovery rate.It the results are shown in Table
4。
4. sample recovery rate measurement result of table
As can be seen from the above table, the rate of recovery is preferable, method is feasible.
Total saponin content measures in each tested number sample solutions of h
Precision draws each tested number sample solution 1ml, develops the color by method below standard curve item, measures and absorbs at 598nm
Degree.Total saponin content in sample is calculated by calibration curve method, the results are shown in Table 1.
2, extraction process by water conclusion
Using the content of extract content and total saposins as index, determine that best testing program is：Add 8 times of amount water, it is small to impregnate 1
When, it extracts 2 times, every time 2 hours.
3, alcohol precipitation process screens
The total 700g of crude drug is weighed by 3 recipe quantity of embodiment, is decocted using the technique that screening is taken out, 600ml is concentrated into, by medicine
Liquid is divided into 3 parts, every part of about 180ml, adjusts content alcohol amount up to 50%, 60%, 70% respectively.It places 24 hours, filtration, filtrate subtracts
Push back receipts ethyl alcohol.Water is added to be settled to 180ml.Three kinds of water extracting alcohol hypostasis 0.6ml are pipetted respectively, cross large pore resin absorption column, equally
Product operate, with vanillic aldehyde perchloric acid determination of color trap.It the results are shown in Table 5.
5 alcohol precipitation concentration of table screens
Find out from table, when alcohol precipitation concentration is 60%, extract is relatively low, and total saposins transfer is higher, therefore with selection
60% concentration of alcohol is best alcohol precipitation concentration.
4, water is heavy
In order to meet the requirement of oral solution clarity, also reply liquid does further removal of impurities to alcohol precipitation later.Through repeated screening,
It determines after alcohol precipitation recycling ethyl alcohol in prescription medicine amount liquid, to add water constant volume 600ml, place 24 hours, take supernatant to filter, then use
40%NaOH adjusts pH value to weakly acidic pH and places, and clarity is preferable.
Illustrate beneficial effects of the present invention below by way of test example
Test example 1, strengthen immunity experiment
1, mouse carbonic clearance is tested
SPF grades of male Balb/c mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) are chosen, 18~22g is randomly divided into 4
Group, every group 12, respectively control group, low (40mL/kg), in (75mL/kg), high (150mL/kg) dosage group.With 0.2ml/
10g volume gastric infusion 30d, 1 time a day, control group gives equivalent distilled water.12h before last dose, is deprived of food but not water.Last
After administration for 24 hours, mouse tail vein injects diluted 25% india ink (Phygene companies), is injected with 0.1mL/10g.Injection
2,10min after prepared Chinese ink takes 20 μ l of blood from angular vein clump respectively, exists side by side and be added into 2mL 0.1%Na2CO3In solution.With
Full-automatic microplate reader densitometric value (OD) at 600nm wavelength, with Na2CO3Solution compares control.It finally will be at small white mouse
Extremely, spleen, liver and thymus gland are taken, organ surface blood stains is blotted with filter paper, weighs.Calculate phagocytic index and organ index.
Phagocytic index=weight/(liver weight+spleen weight) × k1/3, k=(lgOD1-lgOD2)/(t2-t1),
Organ index=(organ weights mg/ mouse weights g) × 10.
6 each group mouse carbonic clearance results contrast of table (N=10)
Note：Compared with compareing control group, * P<0.05, * * P<0.01 (similarly hereinafter)
As known from Table 6, compared with the control group, each administration group phagocytic index is above control group, and low dose group, middle dosage
Group with control group there is significant difference (P ＜ 0.05), each dosage group phagocytic index the trend successively decreased is presented；Each administration group spleen with
Significant difference (P ＜ 0.05) is also presented in thymus index, prompts the present composition to have the monocytes/macrophages function of mouse aobvious
Writing influences.
2, dinitrofluorobenzene (DNFB) inducing mouse Tardive allergy (ear swelling method)
Male Balb/c mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) are chosen, 18~22g is randomly divided into 4 groups, every group
12, respectively control group, low (40mL/kg), in (75mL/kg), high (150mL/kg) dosage group.With 0.2ml/10g volumes
Gastric infusion 30d, is administered once daily, and control group gives equivalent distilled water.After 25d is administered, mouse web portion selection area 3cm ×
The regions 3cm are lost hair or feathers with 8% barium sulphide (Shandong West Asia chemical industry Co., Ltd), are coated with DNFB solution (Shandong West Asia chemistry works
Industry Co., Ltd) 50 μ l sensitization, it is primary that 25 μ l of second day repeat sensitization.After 5d, mouse is uniformly applied to 10 μ l of DNFB solution
Auris dextra (two sides) is attacked.Cervical dislocation puts to death mouse for 24 hours after attack, left and right auricular concha is cut, with card punch in same place
The auricle for removing diameter 8mm, weighs.Mouse thymus, spleen are taken simultaneously, is weighed, mice ear degree and organ index are calculated.
Mice ear degree：Ear swelling degree (mg)=auris dextra tablet quality-left auricle quality,
Organ index=(organ weights mg/ mouse weights g) × 10.
Table 7DNFB induction each group mouse DTH reaction comparison (N=10)
As known from Table 7, compared with the control group, each administration group ear swelling degree is above control group, and middle dose group, high dose
Group ear swelling degree with control group there is significant difference (P ＜ 0.05), each dosage group ear swelling degree incremental trend is presented；Each administration
Group spleen is not significantly different (P ＞ 0.05) with thymus index, and celestial over sixty years of age is prompted to take orally the cellular immunity that liquid energy significantly increases mouse
Function.
Dinitrofluorobenzene (DNFB) is small molecule antigens, skin can be stimulated to generate delayed allergy, which can be anti-
Reflect the power of cell immunocompetent.DTH experiment discoveries, the basic, normal, high 3 dosage agent of 40mL/kg, 75mL/kg, 150mL/kg
Present composition gastric infusion 30d can improve DNFB inducing mouse delayed allergy abilities, and middle and high dosage group
With significant difference, prompts the present composition to have and improve mouse cell immune function.Carbonic clearance is it was found that, each dose
Amount group does not make significant difference to mouse weight growth, thymus index, index and spleen index.But it is wide that each dosage group can improve mouse carbon granules
Clear ability, low, middle dose group have significant difference.
This result of study shows that the present composition can not only improve mouse carbon particle clearance ability, and phagocytic index is made obviously to carry
It is high, moreover it is possible to the Tardive allergy for significantly inhibiting dinitrofluorobenzene induced mice, according to《Health food is examined and assessment technique
Specification》Criterion in (version in 2003) illustrates that the present composition has strengthen immunity effect.
Test example 2 alleviates physical fatigue experiment
1 experimental animal is grouped and medication
SPF grades of health KM mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) are randomly divided into 5 groups, every group 12, are distinguished
For control group, positive group (Oral Liquid Radix Panacis Quinquefolii (Biotechnology Co., Ltd. Fujian well-being)) and low, middle and high dose groups.According to
Human oral's recommended amounts, if the basic, normal, high dosage of oral solution is respectively 40mLkg-1、75mL·kg-1、150mL·kg-1(respectively
It is equivalent to 5,10,20 times of human body recommended amounts), the tested material for giving mouse various dose, blank are adopted according to 0.2ml/10g volumes
Control group gives equivalent distilled water.It is administered once daily, continuous 30d.
2 swimming with a load attached to the body are tested
SPF grades of health KM mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) 60, half male and half female, after last time is administered
It weighs, calculates the front and back body weight growth rate of mouse administration.After last gives by reagent 30min, by 5% weight sheet lead of tail portion load
Mouse be placed in swimming trunk went swimming.The depth of water is no less than 30cm, 25 DEG C of water temperature, and record mouse swimming started to the dead time,
That is the mice burden swimming time.
8 tested material of table to mouse weight and organ index influence (N=10)
Note：* P ＜ 0.05, * * P ＜ 0.01
As shown in table 8, tested material has not significant impact mouse weight growth.Low dose group, high dose group are to mice spleen
Dirty index has a significant impact, and is influenced on thymus index not notable.
9 tested material of table to the mice burden swimming time influence (N=10)
Note：* P ＜ 0.05, * * P ＜ 0.01
As shown in table 9, each dosage group of tested material and positive group are obviously prolonged the mice burden swimming time, with blank control group
Compare, high and low dose group and positive group have notable difference.
3SOD, MDA and hepatic glycogen measure
SPF grades of health KM mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) 60, half male and half female, last dose 30min
Afterwards, eyeball takes blood, detaches serum, and detection SOD in serum, MDA take out rapidly liver after putting to death mouse, prepare liver tissue homogenate, press
Kit specification measures liver SOD, MDA and hepatic glycogen.
10 tested material of table to SOD in Mice, MDA and hepatic glycogen content influence (N=10)
Note：* P ＜ 0.05, * * P ＜ 0.01
As shown in table 10, tested material middle dosage, high dose group and positive group can significantly raised hepatic glycogen content, with blank group
Comparing difference is significant (P ＜ 0.05), and low dose group has no significant effect mouse hepatic glycogen content.To SOD comparision contents
It was found that positive group and administration group can significantly increase SOD in Mice content, compared with blank group, middle dose group, positive group have pole
Significant difference (P ＜ 0.01), low dose group, high dose group have significant difference (P ＜ 0.05).Administration group and positive group can drop
Low mouse MDA contents, compared with blank group, positive group has pole significant difference (P ＜ 0.01), and high dose group can significantly reduce
MDA contents (P ＜ 0.05).
4 serum urea nitrogen determinations
SPF grades of health KM mouse (Company of Animals Ltd. is tested in Chengdu up to rich fruit) 60, it is male, it is randomly divided into 5 groups according to weight.
After last dose 30min, 30cm, water temperature (25 ± 1.0) DEG C water went swimming 90min are no less than in the depth of water.It is quiet after movement
60min plucks eyeball and takes blood, sets 4 DEG C of refrigerator about 3 hours, and 2000r/min centrifuges 15min after blood clotting, serum is detached, by reagent
Box specification operates, and measures serum urea nitrogen content.
11 tested material of table to mice serum urea nitrogen content influence (N=10)
Note：* P ＜ 0.05, * * P ＜ 0.01
As shown in table 11, compared with blank group, each dosage group and positive group Oral Liquid Radix Panacis Quinquefolii can significantly reduce mouse
Serum urea nitrogen content (P ＜ 0.05), and be in dose dependent.
According to《Health food is examined and assessment technique specification》(version in 2003) evaluation present composition is exempted from cell
In epidemic disease function, humoral immune function, monocytes/macrophages function and the detection of NK cell functions, if any more than two (containing two)
Function detection result is positive, you can judges that the tested material has immunoregulation effect.I.e. the present composition, which has, alleviates muscle power
The effect of fatigue function.
This experimental result shows that the present composition has no significant effect the growth of mouse weight and thymus index；It can
Enhance mice serum and liver SOD activity, reduce MDA contents, enhances the ability removed and generated free radicals when body movement；It is aobvious
It writes and improves liver glycogen reserves amount；Blood urea nitrogen is horizontal after reducing mouse swimming.
The present composition is by significantly improving internal antioxidant system enzyme activity, antioxidant defense ability in reinforcement,
Internal oxygen radical is removed, Cell membrane lipids peroxidating is prevented, effectively prevents cellular free radical damage；Improve the storage of body glycogen
Standby, the accumulation of serum urea nitrogen, accelerates dispelling fatigue when enhancing mouse movement endurance and reducing movement.
To sum up, composition of the invention can effectively eliminate fatigue and the immunity of enhancing body.And of the present invention group
Conjunction object is medicinal and edible Chinese medicine, safe and non-toxic, is suitble to be used for a long time, and is suitable for hypoimmunity and excessively tired inferior health
Crowd provides a kind of new selection for clinical application.
Claims (10)
1. a kind of food, health products or pharmaceutical composition, it is characterised in that：It is that the raw material matched by following weight is prepared
Preparation：
200~300 parts of Radix Astragali, 200~300 parts of matrimony vine, 250~400 parts of Herba Epimedii, 150~300 parts of sea-buckthorn.
2. food according to claim 1, health products or pharmaceutical composition, it is characterised in that：The weight of the raw material is matched
Than for：
250 parts of Radix Astragali, 250 parts of matrimony vine, 300 parts of Herba Epimedii, 200 parts of sea-buckthorn.
3. food according to claim 1 or 2, health products or pharmaceutical composition, it is characterised in that：It is by bulk pharmaceutical chemicals
Medicinal powder, the water of bulk pharmaceutical chemicals or extractive with organic solvent are active constituent, in addition the system that acceptable auxiliary material is prepared in pharmacy
Agent.
4. food according to claim 3, health products or pharmaceutical composition, it is characterised in that：The auxiliary material is selected from benzene first
Sour sodium, potassium sorbate, ethyl-para-hydroxybenzoate, propylparaben, butyl p-hydroxybenzoate, stevioside, xylose
It is one or more in alcohol, Aspartame, dextrin, soluble starch, beta-cyclodextrin.
5. according to Claims 1 to 4 any one of them food, health products or pharmaceutical composition, it is characterised in that：The preparation
For oral preparation.
6. food according to claim 5, health products or pharmaceutical composition, it is characterised in that：The oral preparation is
Granula, pill, tablet, capsule, oral solution.
7. a kind of method preparing any one of claim 1~6 food, health products or pharmaceutical composition, it is characterised in that：
It includes the following steps：
(1) each raw material is weighed by weight ratio；
(2) medicinal powder, water or extractive with organic solvent of bulk pharmaceutical chemicals are taken, in addition acceptable auxiliary material or complementary ingredient system in pharmacy
For at preparation.
8. according to the method described in claim 7, it is characterized in that：It includes the following steps：
(1) each raw material is weighed by weight ratio, 8~12 times of water are added, is impregnated 30~60 minutes, is decocted 1~2 hour, and filtering takes
8~12 times of water are added in filter residue, decoct 1~2 hour, filtering, merge filtrate twice, concentration；
(2) concentrate in step (1) is taken, adds ethyl alcohol that alcohol content is made to be 30~70%, stirs evenly, remove ethyl alcohol, concentrate, be added
The water of 1 times of amount of concentrate, stirs evenly, adds auxiliary material.
9. according to the method described in claim 8, it is characterized in that：It includes the following steps：
(1) each raw material is weighed by weight ratio, 8 times of water are added, is impregnated 60 minutes, is decocted 2 hours, and filtering takes filter residue, is added 8
Times water decocts 2 hours, filtering, merges filtrate twice, concentration；
(2) concentrate in step (1) is taken, adds ethyl alcohol that alcohol content is made to be 60%, stirs evenly, removes ethyl alcohol, concentration is added in concentration
The water of 1 times of amount of liquid, stirs evenly, adds auxiliary material.
10. any one of claim 1~6 composition prepare improve immunity and the food relieved fatigue, health products or
Purposes in drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810157269.9A CN108497478A (en) | 2018-02-24 | 2018-02-24 | A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810157269.9A CN108497478A (en) | 2018-02-24 | 2018-02-24 | A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108497478A true CN108497478A (en) | 2018-09-07 |
Family
ID=63375214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810157269.9A Pending CN108497478A (en) | 2018-02-24 | 2018-02-24 | A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108497478A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113244372A (en) * | 2021-04-22 | 2021-08-13 | 建昌帮药业有限公司 | Composition for enhancing immunity and preparation process and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101280476B1 (en) * | 2011-04-12 | 2013-07-01 | 삼성중공업 주식회사 | Propulsion apparatus for ship and ship having the same |
| CN107582898A (en) * | 2017-10-19 | 2018-01-16 | 福建中医药大学 | A kind of antibechic stops pharmaceutical composition of phlegm and its production and use |
-
2018
- 2018-02-24 CN CN201810157269.9A patent/CN108497478A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101280476B1 (en) * | 2011-04-12 | 2013-07-01 | 삼성중공업 주식회사 | Propulsion apparatus for ship and ship having the same |
| CN107582898A (en) * | 2017-10-19 | 2018-01-16 | 福建中医药大学 | A kind of antibechic stops pharmaceutical composition of phlegm and its production and use |
Non-Patent Citations (2)
| Title |
|---|
| 刘素娟等: "仙耆口服液对小鼠缓解体力疲劳作用的实验研究", 《中药与临床》 * |
| 郑赞朴: "《使用自我防癌指南》", 31 December 2017, 中国科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113244372A (en) * | 2021-04-22 | 2021-08-13 | 建昌帮药业有限公司 | Composition for enhancing immunity and preparation process and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100374538C (en) | Fire internal organ nourishing wine and its preparation technology | |
| CN102318857B (en) | Liver-protecting alcoholism-relieving plant beverage and preparation method thereof | |
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN103585400B (en) | Have and strengthen immunologic function and the compositions alleviating fatigue effect and preparation method thereof | |
| CN108157575A (en) | A kind of pressed candy for alleviating visual fatigue and preparation method and application | |
| CN106214845A (en) | A kind of pharmaceutical composition with health care and preparation method thereof | |
| CN101670075B (en) | Traditional Chinese medicine composition for treating depression | |
| CN102233009B (en) | Chinese medicinal composition for promoting nerve regeneration and preparation method and use thereof | |
| CN101816723A (en) | Sobering up and liver protecting Chinese medicinal preparation and preparation method thereof | |
| CN102106890B (en) | Applications and preparation method of saussurea total sesquiterpene lactone | |
| CN107308323A (en) | Cerebrum tonifying oral liquid and its preparation technology | |
| CN108497478A (en) | A kind of food of strengthen immunity, health products or pharmaceutical composition and its preparation method and application | |
| CN107041924A (en) | It is a kind of prevent and treat diabetic nephropathy towards medicine compound extract and preparation method thereof | |
| CN107266599B (en) | Flammulina velutipes, extracting method and its application in terms of functional consitipation drug is treated in preparation | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN107087795A (en) | A kind of anti-fatigue anoxia-tolerance Halth-care composition | |
| CN105533749A (en) | Health food containing herba epimedii and fructus schizandrae and preparing method and application thereof | |
| CN110694025A (en) | Eight-treasure intelligence-benefiting compound and preparation method and application thereof | |
| CN101816698A (en) | Composition for preventing and curing metabolism disturbance syndrome | |
| CN101357156B (en) | Traditional Chinese medicine for curing diabetes and preparation method thereof | |
| CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN102973657A (en) | Scutellaria baicalensis, manchurian lilac bark and dahurian rhododendron leaf cough-arresting mixture and preparation method thereof | |
| CN107648565A (en) | A kind of pharmaceutical composition for treating depression and preparation method thereof | |
| CN108403647A (en) | Cynomorium songaricum anti anoxia buccal tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180907 |
|
| RJ01 | Rejection of invention patent application after publication |